Pembrolizumab-associated hemophagocytic lymphohistiocytosis in recurrent metastatic squamous cell carcinoma of the ovary arising in a teratoma

Background: The expanding use of immune checkpoint inhibitors (ICIs) in gynecologic oncology has been accompanied by an increasing incidence of immune related adverse events (irAEs), requiring rapid recognition and management to prevent significant morbidity and mortality (Conroy and Naidoo, 2022; L...

Descrición completa

Detalles Bibliográficos

Principais autores:	Jenna S. Powers, Olivia W. Foley, Connor C. Wang, Jenna Marcus, Emily Hinchcliff
Formato:	Artigo
Idioma:	Inglês
Publicado:	Elsevier 2026-04-01
Series:	Gynecologic Oncology Reports
Assuntos:	Hemophagocytic lymphohistiocytosis Immune checkpoint inhibitor Pembrolizumab Ovarian squamous cell carcinoma Immune-related adverse events
Acceso en liña:	http://www.sciencedirect.com/science/article/pii/S2352578926000391
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!